Experimental medicine study with stabilised native-like HIV-1 Env immunogens drives long-term antibody responses, but lacks neutralising breadth
Pollock K. et al, (2024), EBioMedicine
Multi-site Ultrasound-guided Fine Needle Aspiration to Study Cells and Soluble Factors From Human Lymph Nodes.
Al-Diwani A. et al, (2024), Curr Protoc, 4
A phase I double-blind trial investigating trachoma vaccine regimens using the Chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02)
Pollock K., (2024), The Lancet Infectious Diseases
Early mucosal events promote distinct mucosal and systemic antibody responses to live attenuated influenza vaccine.
Thwaites RS. et al, (2023), Nat Commun, 14
Antibody responses to Influenza vaccination are diminished in patients with inflammatory bowel disease on infliximab or tofacitinib.
Liu Z. et al, (2023), J Crohns Colitis
P77 Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type strain in patients with IBD after three doses of COVID-19 vaccine
Liu Z. et al, (2023), Poster presentations, A89 - A90
Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.
Writing Committee for the REMAP-CAP Investigators None. et al, (2023), JAMA, 329, 1183 - 1196
COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2
Szubert AJ. et al, (2023), eClinicalMedicine, 56
Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine.
Liu Z. et al, (2023), Gastroenterology, 164, 300 - 303.e3
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Liu Z. et al, (2023), Lancet Gastroenterol Hepatol, 8, 145 - 156
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
Fidler S. et al, (2023), Clin Infect Dis, 76, 201 - 209